G. S. Jakobsen

The association between severity of King’s Obesity Staging Criteria scores and treatment choice in patients with morbid obesity: a retrospective cohort study

E. Aasheim, J. Hjelmesæth, M. Småstuen, 2016, BMC Obesity.

Significant Increase in Systemic Exposure of Atorvastatin After Biliopancreatic Diversion With Duodenal Switch

K. Stormark, A. Åsberg, T. Jenssen, 2010, Clinical pharmacology and therapeutics.

Bariatric surgery and specialized medical treatment for severe obesity. Impact on cardiovascular risk factors and postsurgical pharmacokinetics of atorvastatin

G. S. Jakobsen, 2018 .

Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities

J. Hjelmesæth, M. Småstuen, D. Hofsø, 2018, JAMA.

Significantly Altered Systemic Exposure to Atorvastatin Acid Following Gastric Bypass Surgery in Morbidly Obese Patients

K. Stormark, A. Åsberg, T. Jenssen, 2009, Clinical pharmacology and therapeutics.

Long-term effects of gastric bypass and duodenal switch on systemic exposure of atorvastatin

A. Åsberg, J. Røislien, J. Hjelmesæth, 2012, Surgical Endoscopy.

Bariatric Surgery and Hypertension.

J. Hjelmesæth, G. S. Jakobsen, N. Nordstrand, 2018, JAMA.

[Follow-up after bariatric surgery].

E. Aasheim, J. Kristinsson, J. Hjelmesæth, 2011, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects

T. Andersson, A. Åsberg, E. Molden, 2013, Clinical pharmacology and therapeutics.

Morbidly Obese Patients—Who Undergoes Bariatric Surgery?

J. Røislien, J. Hjelmesæth, D. Hofsø, 2010, Obesity surgery.

Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects

T. Andersson, E. Molden, J. Hjelmesæth, 2013, Clinical pharmacology and therapeutics.